Your browser doesn't support javascript.
loading
PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen, Xuejun; Zeng, Xueyuan; Cheng, Xingxing; Zeng, Xinying; Liu, Jia; Zhang, Yiren; Li, Yesen; Chen, Haojun; Huang, Jinxiong; Guo, Zhide; Chen, Xiaoyuan; Zhang, Xianzhong.
Affiliation
  • Wen X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Zeng X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Cheng X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Zeng X; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Liu J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Zhang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Li Y; Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
  • Chen H; Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
  • Huang J; Department of Nuclear Medicine & Minnan PET Center, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
  • Guo Z; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd, Xiamen 361102, China.
  • Chen X; Departments of Diagnostic Radiology and Surgery, Yong Loo Lin School of Medicine and Faculty of Engineering, National University of Singapore, Singapore 119074, Singapore.
  • Zhang X; Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.
Mol Pharm ; 19(10): 3612-3622, 2022 10 03.
Article in En | MEDLINE | ID: mdl-35652897
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Programmed Cell Death 1 Receptor / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Pharm Journal subject: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Year: 2022 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Programmed Cell Death 1 Receptor / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Pharm Journal subject: BIOLOGIA MOLECULAR / FARMACIA / FARMACOLOGIA Year: 2022 Type: Article Affiliation country: China